BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
Provided By GlobeNewswire
Last update: Mar 20, 2025
Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25
Progression of preclinical next-generation APJ agonists for obesity
Read more at globenewswire.com
